Clinical Report: Association of STMN1 Expression with Chemotherapy in BTC
Overview
This study investigates the prognostic value of STMN1 expression in biliary tract cancer (BTC) and its predictive capacity for chemotherapy responses. High STMN1 expression correlates with inferior overall survival, while low expression is associated with better outcomes from gemcitabine-based chemotherapy.
Background
Biliary tract cancer (BTC) has a poor prognosis, with a 5-year survival rate of only 5%–15%. The effectiveness of standard therapies, including gemcitabine-based chemotherapy, remains suboptimal. Understanding biomarkers like STMN1 that influence treatment responses is crucial for improving patient outcomes.
Data Highlights
Finding
Details
STMN1 and OS
High STMN1 expression correlated with inferior overall survival.
Independent Biomarker
STMN1 identified as an independent adverse prognostic biomarker for OS.
Immune Response
Elevated STMN1 linked to immune response activation and T-cell infiltration.
Therapeutic Responses
Low STMN1 expression associated with benefits from gemcitabine-based chemotherapy.
ICB Efficacy
High STMN1 expression predicted superior responses to immune checkpoint blockade.
Key Findings
STMN1 expression is significantly correlated with inferior overall survival in BTC patients.
Multivariate regression analysis identified STMN1 as an independent prognostic biomarker.
Elevated STMN1 levels are associated with increased CD8⁺ T-cell infiltration and PD-L1 expression.
Patients with low STMN1 expression benefit more from gemcitabine-based adjuvant chemotherapy.
High STMN1 expression predicts better therapeutic responses to immune checkpoint blockade.
Clinical Implications
STMN1 serves as a potential biomarker for predicting treatment responses in BTC, distinguishing between patients who may benefit from chemotherapy versus immunotherapy.
Conclusion
STMN1 expression is a critical factor in determining the prognosis and treatment efficacy in biliary tract cancer.
